Literature DB >> 26428020

FDA drug labeling for pregnancy and lactation drug safety monitoring systems.

Michael F Greene1.   

Abstract

The product label required by the FDA for every drug approved for marketing in the US is a legal document that originates with the company that wants to market the drug, but it must be approved by the FDA. Despite the recognized limitations of registries, the FDA's new labeling rule, effective from July 1, 2015, has given the data available from post-marketing surveillance priority in the new label. For this information to be maximally useful to both providers and consumers, providers must refer as many exposed consumers as possible to the registries, preferably prior to knowledge of the outcomes of the pregnancies. Consumers need to cooperate with the registries to share their health information with as much detail as possible with the registries. It will take years to accumulate a meaningful quantity of information in many of the registries, but they promise to be our best hope for useful counseling information in the future.
Copyright © 2015 Elsevier Inc. All rights reserved.

Mesh:

Substances:

Year:  2015        PMID: 26428020     DOI: 10.1053/j.semperi.2015.08.004

Source DB:  PubMed          Journal:  Semin Perinatol        ISSN: 0146-0005            Impact factor:   3.300


  4 in total

1.  Evaluation of Medicine Exposure During Pregnancy at a Tertiary Center of an Indian State.

Authors:  Manoj Kumar Saurabh; Subodh Kumar; Vikash Maharshi
Journal:  Maedica (Bucur)       Date:  2020-12

2.  The New Pregnancy and Lactation Labeling Rule.

Authors:  Sonia Pernia; George DeMaagd
Journal:  P T       Date:  2016-11

3.  PregOMICS-Leveraging systems biology and bioinformatics for drug repurposing in maternal-child health.

Authors:  Jeffery A Goldstein; Lisa A Bastarache; Joshua C Denny; Jill M Pulley; David M Aronoff
Journal:  Am J Reprod Immunol       Date:  2018-05-04       Impact factor: 3.886

4.  Clinical management of medications in pregnancy and lactation.

Authors:  Lorene A Temming; Alison G Cahill; Laura E Riley
Journal:  Am J Obstet Gynecol       Date:  2016-02-02       Impact factor: 8.661

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.